The IT @ Networking Awards 2010 - Open Competition for Healthcare IT Solutions

The IT @ Networking Awards 2010 (IT @ 2010) is an open competition for fully implemented, operable healthcare IT solutions. The goal is to raise awareness of some of the world's finest and most innovative local, regional and national healthcare IT projects.

Recognition
High-tech, high-cost medicine; ageing populations; patient mobility and staff shortages are only some of the challenges healthcare providers face today. Intelligent IT solutions increase cost-effectiveness, productivity and safety and help healthcare facilities to confront these problems. IT @ 2010 brings these innovations into the global spotlight and provides them with the recognition and media attention they deserve.

Their stories will inspire others, proving that challenges can be transformed into future opportunities and success stories.

Novel and Interactive
The core aim of IT @ 2010 is to learn from the mistakes and achievements of different top IT installations. Our unique peer-to-peer voting system empowers daily users such as CEOs, CIOs, CMIOs, hospital and IT managers to vote for their preferred projects, as they are best placed to judge the real value of projects.

First Day - MindByte Session
All Nominees will present in the MindByte, a five minute introductory presentation followed by a lively five minute Q&A. The qualifying audience will vote immediately after each presentation according to the voting criteria for their favourite solution.

Becoming a Nominee is a huge achievement and each will be awarded the prestigious IT @ 2010 Nominee Silver Medal.

Second Day - WorkBench Session
The nine top-rated Nominees will progress as Finalists into the next day WorkBench, a 30-minute in-depth presentation followed by a 15 minute Q&A discussion, providing the audience with a thorough understanding of the project. The qualifying audience will vote immediately after each presentation to choose the winners. Finalists will be awarded the prestigious IT @ 2010 Finalist Gold Medal.

The Prize
The top three IT solutions will be awarded a prize.

THE WINNING PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy;
A cash prize of € 5,000;
Media promotion in Europe's leading healthcare management media worth € 50,000.

THE 2ND PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy;
Media promotion in Europe's leading healthcare management media worth € 25,000.

THE 3RD PROJECT WILL RECEIVE:
The IT @ Networking Awards 2010 Trophy.

How to submit your project?
All entries must already be implemented in at least one site and must be fully operable. All projects must be presented in accordance to the voting criteria. The maximum length of the abstract is 300 words.

For your chance to win, please enter your submission through www.conftool.com/itawards2010

Submission deadline for the Abstract is 25 June 2010.

All project submissions (Abstracts) will be presented to the IT @ 2010 Review Committee. This Review Committee will decide the top 25 IT solutions that will become Nominees and will take part in the MindByte Session.

Submissions without any commercial interest or any link to healthcare service providers are free. All the others are charged a one time registration fee of 1000 EUR.

All nominees are required to submit a 5 minute PowerPoint or Keynote presentation for the first MindByte Session. This is your chance to explain to the audience what differentiates your solution and what makes it special.

Submission deadline for the MindByte Presentation is 31 August 2010.

As a nominee you are also required to submit a 30-minute presentation for the second day WorkBench Session.

Submission deadline for the Workbench Presentation is 20 September 2010.

For further information and registration, please visit:
http://itandnetworking.org

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...